Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions

NCT ID: NCT02404077

Last Updated: 2017-04-20

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 712 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2017-03-31

Brief Summary

The investigators' clinical practice makes use of oral clonidine as a means of transitioning from intravenous dexmedetomidine following prolonged infusions (more than 3-5 days). Although this is common clinical practice, there is limited clinical data to demonstrate the efficacy of this technique and to provide clonidine dosing guidelines. The purpose of this study is to retrospectively review the investigators' experience with the use of oral clonidine to prevent withdrawal following the prolonged administration of dexmedetomidine.

Conditions

Sedation

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Clonidine

Patients who received clonidine following prolonged dexmedetomidine infusions

Clonidine

Intervention Type: DRUG

Interventions

Clonidine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients who received clonidine during the transition from dexmedetomidine.

Exclusion Criteria

• None

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Joseph D. Tobias

OTHER

Sponsor Role: lead

Responsible Party

Joseph D. Tobias

Chairman, Dept. of Anesthesiology & Pain Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Joseph D Tobias, MD

Role: PRINCIPAL_INVESTIGATOR

Nationwide Children's Hospital

Other Identifiers

IRB15-00256

Identifier Type: -

Identifier Source: org_study_id